Rate My Professor Amy Buckley

Dr. Amy Buckley is a Lecturer in Pharmacology in the School of Health at the University of New England within the Faculty of Medicine and Health. She holds a BSc (Hons) majoring in Pharmacology from University College Dublin and a PhD from Trinity College Dublin, awarded in 2019. Her doctoral research at the Trinity Translational Medicine Institute, under the supervision of Professor Jacintha O’Sullivan, explored the potential of novel small molecule compounds to enhance radiosensitivity in oesophageal adenocarcinoma.

Prior to joining UNE in 2024, Dr. Buckley conducted postdoctoral research at Queensland University of Technology with Professor David Waugh at the Translational Research Institute in Brisbane. She subsequently served four years as a Senior Evaluator in the chemical review team at the Australian Pesticides and Veterinary Medicines Authority. At UNE, she is also a Senior Lecturer in Pharmacology and Course Coordinator for the Bachelor of Pharmacy with Honours, teaching units including Pharmacology I (PHAR222), Pharmacology II (PHAR330), and Research Project in Pharmacy (PHAR402H).

Dr. Buckley’s research specializations include oesophageal adenocarcinoma, treatment resistance, radioresistance, and drug development. Her key publications feature Buckley et al., 'Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers', Nature Reviews Gastroenterology & Hepatology (2020); Buckley et al., 'Pyrazinib (P3),[(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma', Cancer Letters (2019); Buckley et al., 'Characterisation of an isogenic model of cisplatin resistance in oesophageal adenocarcinoma cells', Pharmaceuticals (2019); Buckley et al., 'Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma', Oncotarget (2018); and Buckley et al., 'Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib', Scientific Reports (2020). Her publications have received 389 citations.